AIBioTech partners with AutoGenomics to expand Molecular Testing
Richmond, VA/Carlsbad, CA, January 6, 2010 - American International Biotechnology Services™ (AIBioTech™), a division of Bostwick Laboratories®, announced today that it has established a partnership with AutoGenomics wherein they will utilize the automated INFINITI® analyzer and multiple applications that they have validated.
“The automation provided by AutoGenomics’ INFINITI® Analyzer has enhanced workflow in our laboratories,” said William Miller, CEO of AIBioTech. He further stated that “with their expanding menu of molecular applications we have found AutoGenomics to be very responsive in meeting our emerging testing needs.”
“We are excited at this partnership and impressed with the test portfolio that is being offered by AIBioTech,” said Fareed Kureshy, CEO of AutoGenomics. “The versatility of our BioFilmChip Microarray technology allows us to rapidly develop new applications to meet the needs of AIBioTech.”
About American International Biotechnology Services (AIBioTech)
AIBioTech provides drug discovery and diagnostic development organizations a broad range of world-class laboratory services to bring new products to market, including laboratory services for molecular biology, microbiology, virology, immuno peptide, bioorganic, and protein chemistries.
AIBioTech is one of the world's most comprehensive Contract Research Organizations. As an expert core laboratory, AIBioTech provides consultation on experimental design and offers services under GLP and non-GLP compliance. These services are offered individually or can be integrated to support product development from discovery-to-market with full Regulatory Support under FDA GLP Guidelines 21 CFR 58. For more Information, please visit www.aibiotech.com
AutoGenomics Inc., a privately held company based in Carlsbad, CA, has developed the first automated, microarray based multiplexing diagnostic platforms that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed leading to the era of personalized medicine. For more Information, please visit www.autogenomics.com
For further information please contact:
Senior Vice President Sales & Marketing, AutoGenomics
760-804-7378 x 305